Rimonabant: Obesity: Loss of a few kilos, many questions

Prescrire International

Volumn 15, Issue 84, 2006, Pages 123-126

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; ANTIOBESITY AGENT; GLYCOSYLATED HEMOGLOBIN; LACTONE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; TRIACYLGLYCEROL LIPASE;

ANXIETY DISORDER; ARTICLE; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DIZZINESS; DRUG FATALITY; DRUG INDICATION; DRUG MARKETING; DRUG WITHDRAWAL; EUROPE; EXERCISE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HUMAN; HYPERALGESIA; IMPOTENCE; INSOMNIA; LIBIDO DISORDER; LIPID ANALYSIS; LONG TERM CARE; MENTAL DISEASE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; MULTIPLE SCLEROSIS; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; PRESCRIPTION; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SMOKING CESSATION; WEIGHT GAIN; WEIGHT REDUCTION; BLOOD; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG APPROVAL; DRUG EFFECT; LOW CALORY DIET; RANDOMIZED CONTROLLED TRIAL; SMOKING; TREATMENT OUTCOME; UNITED STATES;

ANTI-OBESITY AGENTS; CHOLESTEROL, HDL; DIET, REDUCING; DOUBLE-BLIND METHOD; DRUG APPROVAL; EUROPE; EXERCISE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LACTONES; LIPASE; METABOLIC SYNDROME X; OBESITY; PIPERIDINES; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, CANNABINOID, CB1; SMOKING; TREATMENT OUTCOME; UNITED STATES; WEIGHT LOSS;

EID: 33746417528     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. "rimonabant". Website www.iddb.com accessed 1 March 2006.
2. Di Marzo V et al. "The endocannabinoid system and its therapeutic exploitation" Nat Rev Drug Discov 2004; 3: 771-784.
3. Howlett AC "The cannabinoid receptors" Prostaglandins Lipid Mediat 2002; 68-69: 619-631.
4. Cohen C et al. "S 141716, on central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats" Behav Pharmacol 2002; 3: 451-463.
5. Pi-Sunyer FX et al. "Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients" JAMA 2006; 295 (7): 761-775 + erratum (11): 1252.
6. Van Gaal LF et al. "Effects of the cannabinoid-1-receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study" Lancet 2005; 365: 1389-1397 + erratum (9483): 370.
7. "Effect of rimonabant on weight reduction and cardiovascular risk" (letters) Lancet 2005; 366: 367-370.
8. Desprès JP et al. "Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia" N Engl J Med 2005; 353 (20): 2121-2134.
9. Scheen A "Communiqué de presse: one étude avec le rimonabant montre une amélioration significative de l'HbA1c et des facteurs de risque cardiométabolique chez les patients diabétiques de type 2" 12 June 2005: 4 pages.
10. Kimmon D "Data shows new drug rimonabant, helps smokers quit while limiting post cessation weight gain" 9 March 2004: 5 pages.
11. Prescrire Editorial Staff "Orlistat" Prescrire int 2002; 11 (57): 10-12.
12. Prescrire Editorial Staff "Sibutramine" Prescrire Int 2001; 10 (55): 140-145.
13. Sanofi Aventis "Sanofi Aventis reçoit de la FDA une « approvable letter » pour le rimonabant dans la prise en charge de l'obésité et une « non approvable letter » dans le sevrage tabagique" 17 February 2006: 1 page.
14. European Medicines Agency "Committee for medicinal products for human use - Summary of positive opinion for Acomplia" 27 April 2006. Website http://www.emea.eu.int accessed 28 April 2006.
15. U.S. National Institutes of Health "Information on clinical trials and human research studies" Website clinicaltrials.gov accessed 11 March 2006.